Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), announced that Interim Chief Executive Officer Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The discussion is scheduled for June 4, 2026, at 2:35 p.m. EDT and will be webcast live, with a replay available through the Events & Presentations section of the company’s investor relations website. This event provides an opportunity for Helus Pharma to discuss its pipeline and clinical progress with investors and industry analysts. The full press release is available at https://ibn.fm/1QdP7.
Helus Pharma is developing proprietary NSAs designed to activate serotonin pathways that are believed to promote neuroplasticity, aiming to address unmet needs in depression, anxiety, and other mental health conditions. The company’s lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. The company also maintains an extensive research portfolio of investigational NSAs.
The Jefferies Global Healthcare Conference is a key industry event where companies present to investors and stakeholders. Helus Pharma’s participation highlights its commitment to advancing its pipeline and communicating its strategy. The fireside chat will likely cover clinical data, regulatory milestones, and future plans. For updates, investors can visit the company’s newsroom at https://ibn.fm/HELP.
Helus Pharma operates in Canada, the United States, the United Kingdom and Ireland. The company, formerly known as Cybin Inc., was founded in 2019 and is focused on helping minds heal through innovative therapies. With class-leading data, Helus Pharma aims to improve the treatment landscape for mental health conditions. The company’s website is www.helus.com.
The announcement of Helus Pharma’s conference participation is significant as it provides a platform to showcase its clinical advancements and potentially attract investment. The company’s progress in Phase 3 and Phase 2 trials positions it as a notable player in the mental health therapeutics space. Investors and industry observers will be watching for updates on HLP003 and HLP004, as well as any new developments from the research pipeline. The webcast replay will allow broader access to the discussion, ensuring that stakeholders can stay informed about the company’s trajectory.
This article has been disseminated on behalf of Helus Pharma and may include paid advertising. For more information, visit https://www.BioMedWire.com.
